A specific strain of reovirus (T1L) triggers a type I interferon signal that brings natural killer cells to gut lymph nodes, where they release type II interferon and activate immune cells that prevent the body from tolerating new food proteins.
Evidence from Studies
Supporting (1)
Community contributions welcome
NK cells contribute to reovirus-induced IFN responses and loss of tolerance to dietary antigen
A specific virus (T1L) tricks the body’s immune system into attacking harmless food, but another version (T3D-RV) doesn’t. This happens because T1L wakes up special immune cells (NK cells) that then stir up more inflammation, breaking the body’s tolerance to food.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether reovirus strain T1L-specific immune signatures are consistently linked to loss of oral tolerance across human cohorts with celiac disease.
A systematic review and meta-analysis of published studies comparing reovirus strain-specific serology, type I/II IFN signatures, and NK cell activation in children with celiac disease versus controls, stratified by HLA-DQ2/DQ8 status.
Whether blocking type I interferon signaling during early reovirus infection prevents NK cell activation and loss of oral tolerance in genetically susceptible individuals.
A double-blind RCT in 150 HLA-DQ2/DQ8-positive infants, randomized to receive anti-IFNAR antibody or placebo during first reovirus exposure, with monitoring of NK cell activation, type II IFN levels, and Treg/Th1 balance at 6 and 12 months.
Whether type I interferon responses following reovirus infection predict subsequent NK cell activation and loss of oral tolerance in genetically predisposed children.
A prospective cohort of 800 HLA-DQ2/DQ8-positive infants, with monthly serum IFN-α/β measurements after first reovirus infection, followed by NK cell phenotyping and oral antigen challenge at 6 months, tracking development of celiac autoantibodies over 5 years.
Whether children with celiac disease have higher type I interferon responses during reovirus infection compared to asymptomatic carriers.
A matched case-control study comparing type I IFN levels and NK cell activation in 100 children with recent celiac diagnosis to 200 asymptomatic HLA-matched controls, using archived serum samples collected at time of first reovirus infection.
Whether reovirus seropositivity correlates with type I interferon signatures and NK cell activation in individuals with celiac disease.
A cross-sectional analysis of 250 adults with celiac disease and 250 controls, measuring serum reovirus antibodies, plasma IFN-α levels, and peripheral NK cell activation markers (CD69, IFN-γ) in a single time point.